Company: BNBX
Filing Date: 2025-10-30
Form Type: S-1
Source: 0001104659-25-103871
Chunk: 207

Company: BNB PLUS CORP.
Filing Date: 2025-10-30
Form: S-1
Chunk 207
---
 15,000 |   | $         |  16,000 |   | $        |  262,000 | ​ | $      |  320,000 |
| Change in fair value          | ​ | ​        | -26,900 | ​ | ​        | -14,990 | ​ |           | -15,950 | ​ |          | -261,000 | ​ | ​      | -318,840 |
| Fair Value at June 30, 2025   | ​ | $        |     100 | ​ | $        |      10 | ​ | $         |      50 | ​ | $        |    1,000 | ​ | $      |    1,160 |

F-51

NOTE J – DISCONTINUED OPERATIONS

On June 27, 2025, the Company implemented a strategic restructuring and realignment of resources to focus exclusively on its Therapeutic DNA Production Services business. As part of actions undertaken, the Company implemented a workforce reduction of approximately % of its then current headcount and has ceased operations at ADCL.

The Company’s actions are intended to reduce its operating costs and concentrate resources on the development and commercialization of its Therapeutic DNA Production Services business. The Company expects to pay approximately three hundred thousand dollars ($) in one-time charges related to the June 30, 2025, workforce reduction and ceasing of operations at ADCL, primarily for separation benefits. As a result of this restructuring, the operations and financial results of ADCL have been accounted for as discontinued operations.

The following table presents the major classes of ADCL’s results within Net loss from discontinued operations, net of tax in the condensed consolidated statement of operations:

| ​                                                 
 ​                                                 | ​ 
 ​ | ​    
 ​    
 2025 |                           ​ 
 Three months Ended June 30, | ​ | ​    
 2024 |       ​ | ​ | ​    
 ​    
 2025 |                          ​ 
 Nine months Ended June 30, | ​ | ​    
 2024 |        ​ |
|:--------------------------------------------------|:--|:-----|----------------------------:|:--|:-----|--------:|:--|:-----|---------------------------:|:--|:-----|---------:|
| Clinical laboratory service revenues              | ​ | $    |                      26,050 | ​ | $    | 324,730 | ​ | $    |                    572,928 | ​ | $